Webinar: PHASE I cGMP DRUG MANUFACTURING AT THE CRU:3 KEY BENEFITS

Sponsored by: Covance

Focused on:

  • Drug Manufacturing
  • Clinical Research

Date: 6 June

111

Time: 4PM London/11AM New York

Drug manufacturing can make up to 40 percent of the total cost to develop a new chemical entity and can be an inflexible, time consuming and frustrating experience during your first-in-human clinical trial. But it doesn’t have to when you use a cGMP pharmacy at your clinical research unit (CRU) for Phase I drug manufacturing. Our approach yields benefits in quality and safety, timeline reduction and cost efficiency.

Join us for an interactive webinar with Dr. Stavchansky, who led the design and implementation of the only cGMP pharmacy in a US CRU. He will share his experience and expertise to help you make informed decisions about the design, monitoring and control of your Phase I drug manufacturing.

Presented by

Marcus Stavchansky, PharmD,

Director, Pharmacy Services NA CPS

Dr. Stavchansky is director of pharmacy services for Covance Clinical Pharmacology Services, overseeing four pharmacy teams at clinical research units (CRUs) in North America. He has 15 years of experience as a registered pharmacist in Texas and eight years of experience in the Phase I CRU space.

Key Learning Objectives

  • Learn how cGMP at the CRU provides high quality, shorter timelines, less API waste, reduced costs and a neutral risk for your program when compared to the alternatives.

Audience

  • Operations
  • R&D
  • Rare Disease and Orphan Drug Clinical Studies